Bel-7402 Xenograft Model Service for Liver Cancer

The Bel-7402 cell line serves as a highly reliable in vivo platform for investigating hepatocellular carcinoma (HCC) progression and therapeutic response. As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision Bel-7402 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your liver cancer drug discovery and development pipeline.

Overview of Bel-7402 Xenograft Model for Liver Cancer

The Bel-7402 xenograft model is an established in vivo translational system widely utilized in oncology research for the study of hepatocellular carcinoma. By transplanting human Bel-7402 cells into immunodeficient rodent hosts, this model effectively reproduces the solid tumor growth characteristics, histological architecture, and vascularization patterns typical of primary human liver malignancies.

Biologically, the Bel-7402 model is highly valued for its consistent tumor formation and predictable growth kinetics, which provide investigators with a robust experimental window for evaluating pharmacological interventions. This model preserves key molecular features of HCC, including high proliferative capacity and susceptibility to conventional chemotherapeutic agents as well as targeted inhibitors. Consequently, the Bel-7402 model is extensively deployed in pre-clinical screening programs to assess the anti-tumor potency of novel small-molecule inhibitors, monoclonal antibodies, and combination therapeutic regimens in a physiologically relevant in vivo setting.

Fig 1. Tubulin folding cofactor E (TBCE) is upregulated in chemoresistant HCC and indicates worse prognosis and earlier relapse. (Li S, et al., 2023)

Cell Line Information: Bel-7402

The Bel-7402 cell line is derived from human hepatocellular carcinoma tissue. These cells exhibit rapid proliferation in vitro and retain a stable phenotype suitable for creating reproducible tumor models for cancer research.

Our Services

Workflow of Bel-7402 Xenograft Model Construction

• Cell Culture & Quality Control: Human Bel-7402 cells are expanded in vitro using standardized nutrient media under optimal incubation conditions. STR authentication and mycoplasma testing are performed prior to inoculation to ensure genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient mice (e.g., BALB/c nude or NCG mice) are selected to support tumor take. Animals are acclimatized to facility conditions prior to the experimental procedures.
• Precision Inoculation: High-viability Bel-7402 cells are prepared in a sterile cell suspension, frequently combined with an extracellular matrix (e.g., Matrigel) to enhance take rates. Cells are inoculated in vivo via subcutaneous injection into the flank region to facilitate the formation of a measurable solid tumor.
• Longitudinal Monitoring: Tumor dimensions are measured regularly using digital calipers to calculate tumor volume. General health and body weight are monitored throughout the study to assess systemic toxicity.
• Randomization & Treatment: Upon reaching a predetermined tumor volume, animals are randomized into experimental cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. Bel-7402 Xenograft Model Construction Workflow

Case Study - Bel-7402 Xenograft Model Development

A pre-clinical validation study was conducted using the Bel-7402 xenograft model to evaluate the therapeutic efficacy of a novel anti-HCC compound. Following subcutaneous inoculation of human Bel-7402 cells into immunodeficient mice, the animals developed palpable, rapidly expanding solid tumors. Animals treated with the investigative agent demonstrated a statistically significant inhibition of tumor growth compared to the vehicle control group, confirming the model's high sensitivity and predictive reliability for screening novel liver cancer therapeutics.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse solid tumor lineages, providing highly reproducible in vivo translational platforms for liver cancer research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your liver cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our Bel-7402 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.